- An immunomodulator
-
The present invention discloses an immunomodulator, specifically relates to a class of compounds inhibiting IL-17A and its use as an immunomodulator in the preparation of drugs. The present invention discloses a compound shown in formula I, or a stereoisomer thereof in the preparation of inhibiting IL-17A class of drugs, for clinical screening and / or preparation of drugs associated with IL-17A activity related to the drug provides a new option.
- -
-
Paragraph 0170-0173
(2022/01/20)
-
- Immunomodulator
-
The invention provides an immunomodulator, and belongs to the field of medical chemistry. The immunomodulator is a compound represented by formula I, or a stereoisomer, or a salt, or a solvate, or a prodrug, or a metabolite thereof. The compound disclosed by the invention shows good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor, is used for treating diseases with abnormal IL-17A activity, and the invention provides a new medicinal possibility for clinically treating diseases related to abnormal IL-17A activity.
- -
-
Paragraph 0274-0278
(2021/02/10)
-
- Immunomodulator
-
The invention discloses an immunomodulator, and particularly relates to a compound shown as a formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Experiments prove that the compound has good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor and drugs for preventing and/or treating IL-17A mediated diseases (such as inflammation, autoimmune diseases, infectious diseases, cancers and precancerous syndromes), and provides a new medical possibility for clinical treatment of diseases related to abnormal IL-17A activity.
- -
-
Paragraph 0472-0475
(2021/02/10)
-
- Immunomodulator
-
The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.
- -
-
Paragraph 0254; 0373-0376
(2021/05/22)
-
- Synthesis of Vicinal Quaternary All-Carbon Centers via Acid-catalyzed Cycloisomerization of Neopentylic Epoxides
-
We report our studies on the development of a catalytic cycloisomerization of 2,2-disubstituted neopentylic epoxides to produce highly substituted tetralins and chromanes. Termination of the sequence occurs via Friedel-Crafts-type alkylation of the remote (hetero)arene linker. The transformation is efficiently promoted by sulfuric acid and proceeds best in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) as the solvent. Variation of the substitution pattern provided detailed insights into the migration tendencies and revealed a competing disproportionation pathway of dihydronaphthalenes.
- Schmid, Matthias,Sokol, Kevin R.,Wein, Lukas A.,Torres Venegas, Sofia,Meisenbichler, Christina,Wurst, Klaus,Podewitz, Maren,Magauer, Thomas
-
supporting information
p. 6526 - 6531
(2020/09/02)
-
- Nickel-catalyzed directed sulfenylation of sp2 and sp3 C-H bonds
-
Directed sulfenylation of both sp2 and sp3 C-H bonds was achieved through nickel catalyzed directed C-S bond formation, giving the desired product in good to excellent yield (up to 90%). Other metal cations, including Cu, Fe, Pd, Rh, Ru and Co, gave almost no reaction under identical conditions, which highlighted the unique reactivity of this Ni system.
- Ye, Xiaohan,Petersen, Jeffrey L.,Shi, Xiaodong
-
supporting information
p. 7863 - 7866
(2015/05/13)
-
- N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
-
Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
- -
-
Paragraph 0.384
(2014/09/30)
-
- N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
-
Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
- -
-
Paragraph 0259
(2014/09/29)
-
- β-Arylation of carboxamides via iron-catalyzed C(sp3)-H bond activation
-
A 2,2-disubstituted propionamide bearing an 8-aminoquinolinyl group as the amide moiety can be arylated at the β-methyl position with an organozinc reagent in the presence of an organic oxidant, a catalytic amount of an iron salt, and a biphosphine ligand at 50 C. Various features of selectivity and reactivity suggest the formation of an organometallic intermediate via rate-determining C-H bond cleavage rather than a free-radical-type reaction pathway.
- Shang, Rui,Ilies, Laurean,Matsumoto, Arimasa,Nakamura, Eiichi
-
p. 6030 - 6032,3
(2013/05/22)
-
- AKT INHIBITORS
-
The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
- -
-
Page/Page column 34
(2011/05/06)
-
- (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES
-
The invention relates to 5,6 - dihydropyrrolo [2,1-a] isoquinoline and pyrrolo[2,1-a] isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
- -
-
Page/Page column 120-121
(2009/10/09)
-
- NOVEL COMPOUNDS
-
A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1 is H, C1-6alkyl, - C(A)D, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4/sub
- -
-
Page/Page column 37
(2008/06/13)
-
- COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
-
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
- -
-
Page/Page column 42-43
(2008/06/13)
-
- Interfacial layer interactions: Their effects on synclinic and anticlinic smectic mesophase behaviour in liquid crystals
-
Through the use of bulky cyclic terminal groups, anticlinic smectic C phases have been observed in 2-methylbutyl materials based on the MHPOBC motif. The Royal Society of Chemistry 2006.
- Cowling, Stephen J.,Goodby, John W.
-
p. 4107 - 4109
(2007/10/03)
-
- ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS
-
The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio
- -
-
Page/Page column 48
(2010/11/08)
-
- Cyclopentanone Synthesis by Intramolecular Carbon-Hydrogen Insertion of Diazo Ketones. A Diterpene-to-Steroid Skeleton Conversion
-
Intramolecular carbon-hydrogen insertion on cupric sulfate assisted decomposition of diazomethyl ketones derived from four 1-methylcycloalkanecarboxylic acids and (hexahydrophenyl)acetic, homopivalic, and enanthic acids is shown to yield mostly cyclopentanones.The yields are appreciable in the conformationally favorable cases, and insertion in the solvent cyclohexane can be avoided by the use of Freon TF as the solvent.The conversion of a primaradienic diterpene into a 14-iso-16-androstanone derivative shows the power of the new method of cyclopentanone synthesis.
- Wenkert, Ernest,Davis, Linda L.,Mylari, Banavara L.,Solomon, Mary F.,Silva, Roberto R. da,et al.
-
p. 3242 - 3247
(2007/10/02)
-
- The Kinetics and Mechanism of Ring Opening of Radicals containing the Cyclobutylcarbinyl System
-
The kinetic parameters of β-fission of radicals containing the cyclobutylcarbinyl system have been determined by analysis of the mixtures obtained when suitable chloro-compounds are treated with tributylstannane.Under these conditions ring opening is irreversible and in the rigid bicyclic system (4) is under stereoelectronic control.For ring opening of cyclobutylcarbinyl radical (8) kf = 4.3 x 103 s-1 at 60 deg C, and the best values of the activation parameters appear to be ΔH(excit.) = 12.2 kcal mol-1 and ΔS(excit.) = -7.4 cal mol-1 K-1.Monocyclic systems undergo preferential fission of the more substituted βγ-bond.Methyl substituents at the α-, β-, or δ-positions have little effect but γ-substitution strongly enhances the rate of ring opening.The transition state is reactant-like and has a similar disposition of centres to that (1) for homolytic addition.
- Beckwith, Athelstan L. J.,Moad, Graeme
-
p. 1083 - 1092
(2007/10/02)
-
- Cyclobutyl substituted derivatives of prostaglandin analogs
-
Novel C15 cyclobutyl analogs or derivatives of prostaglandins of the E-, A- and F-classes are useful modifiers of smooth muscle activity. The compounds have valuable pharmacological properties such as platelet antiaggregating agents, gastric antisecretory agents and brochodilating agents.
- -
-
-